Nature of tumor rejection antigens in ovarian cancer.
Immunology. 2018 May 17;:
Authors: Want MY, Lugade AA, Battaglia S, Odunsi K
Major progress in the analysis of human immune responses to cancer has been made through the molecular characterization of human tumor antigens. The development of therapeutic strategies for eliciting immune-mediated rejection of tumors has accelerated due to the elucidation of the molecular basis for tumor cell recognition and destruction by immune cells. Of the various human tumor antigens defined to date in ovarian cancer, the cancer-testis (CT) family of antigens have studied extensively pre-clinically and clinically due their testis-restricted expression in normal tissues and ability to elicit robust immune responses. Recent developments in cancer sequencing technologies offer a unique opportunity to identify tumor mutations with the highest likelihood of being expressed and recognized by the immune system. Such mutations, or neoantigens, could potentially serve as specific immune targets for T cell mediated destruction of cancer cells. This review will highlight current work in selecting tumor rejection antigens in ovarian cancer for improving the efficacy of immunotherapy. This article is protected by copyright. All rights reserved.
PMID: 29772069 [PubMed – as supplied by publisher]